In those HCL patients in whom no BRAF V600E mutation could be detected, alternative molecular mechanisms that activate the RAS-BRAF-MEK-MAPK pathway in capitulating the HCL phenotype are likely involved. Here, MAP2K7 is linked to hairy cell leukemia.